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Abstract 
Signal transducer and activator of transcription 3 (Stat3) is implicated in the pathogenesis of 
many malignancies and essential for IL-6-dependent survival and growth of multiple myeloma 
cells. Here, we demonstrate that the gene encoding oncogenic microRNA-21 (miR-21) is 
controlled by an upstream enhancer containing two Stat3 binding sites strictly conserved since 
the first observed evolutionary appearance of miR-21 and Stat3. MiR-21 induction by IL-6 was 
strictly Stat3-dependent. Ectopically raising miR-21 expression in myeloma cells in the absence 
of IL-6 significantly reduced their apoptosis levels. These data provide strong evidence that 
miR-21 induction contributes to the oncogenic potential of Stat3. 
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Introduction 
Stat3, the major mediator of IL-6 signaling,1,2 participates in cellular transformation and 
oncogenesis.3,4 Its activation is essential for the transforming potential of many oncogenes. 
Previously, we could show that Stat3 activation is required for IL-6-dependent growth and 
survival of the human myeloma cell lines INA-6 and XG-1.5 Although microarray analyses 
revealed that in these cells the vast majority of IL-6 target genes is controlled through Stat3, 
differential expression of known apoptosis regulators, e.g. members of the Bcl-2 family, could 
not sufficiently account for the observed Stat3-mediated survival effect.5 We therefore searched 
for additional mechanisms through which Stat3 may suppress apoptosis in cancer cells.  
MicroRNAs (miRNAs) are an abundant class of short non-protein-coding RNAs (ncRNAs) 
mediating posttranscriptional down-regulation of target genes. They have been shown to play a 
fundamental role in diverse physiological and pathological processes including proliferation, 
apoptosis, differentiation, and cell fate determination.6,7 Recent evidence indicates that miRNAs 
can function as tumor suppressors and oncogenes.8 Hence, we reasoned that miRNAs might be 
implicated in the Stat3-mediated survival of myeloma cells. 
 
Materials and Methods 
A detailed description of the bioinformatic procedures and the vectors and primer sequences used 
is given as supplemental material. 
INA-6 and XG-1 myeloma and HepG2 hepatocellular carcinoma cells were cultivated and 
reporter gene assays performed as recently described.5,9 
Chromatin immunoprecipitation was performed using a kit (EZ ChIP) from Upstate (Lake Placid, 
NY, USA) according to the manufacturer's instructions. Co-immunoprecipitated DNA was 
amplified using primers specific for the miR-21 upstream region and analysed on an agarose gel. 
Anti-Stat3 serum (PA-ST3) was from R&D Systems (Wiesbaden, Germany). 
RNA interference knock-down of Stat3 and overexpression of miR-21 in myeloma cells was 
performed by electroporation with pSUPER vectors as described.9 Shortly, 1 µg of green 
fluorescence protein expression vector pEGFP-N1 (Clontech, Mountain View, CA, USA) and 19 
µg of expression vectors encoding either a small hairpin RNA targeting Stat3 mRNA (pSUPER-
siStat3)9 or precursor miR-21 (pSUPER-miR-21), or a pSUPER control vector were 
electroporated into 5 x 106 cells. For each experiment, 3 x 107 cells were combined and 
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successfully transfected, green fluorescent cells sorted 48 h posttransfection using a FACS-
Vantage Sorter (BD Biosciences, Heidelberg, Germany).  
For real-time PCR of Stat3 mRNA and primary miR-21 transcripts (pri-miR-21), total RNA was 
prepared using the mirVana miRNA Isolation Kit (Ambion, Austin, TX, USA) and quantified by 
the RNA 6000 LabChip Kit (2100 Bioanalyzer, Agilent Technologies, Waldbronn, Germany). 
Reverse transcription was done with the SuperScript III First-Strand Synthesis System for RT-
PCR (Invitrogen, Karlsruhe, Germany). Real-time PCR was performed using a LightCycler 
(Roche, Mannheim, Germany). An optimal PCR reaction was established with the FastStart DNA 
Master SYBR Green I Kit (Roche, Mannheim, Germany), and it was taken care that only one 
PCR product was generated. Specificity of amplification was validated by confirming the identity 
of PCR products by sequencing. Mature miR-21 was detected by stem-loop reverse transcription 
followed by real-time PCR.10 Signals were normalized to values obtained for glyceraldehyde-3-
phosphate dehydrogenase.  
Apoptosis was detected by flow-cytometry using annexin-V staining as previously described.5  
 
Results and Discussion 
To investigate whether Stat3 is involved in the regulation of miRNA genes, we analysed the 
genomic distribution of Stat3 binding sites and their correlation with known miRNAs by 
phylogenetic footprinting (for details, see supplemental material). Among the miRNA genes 
associated with evolutionarily conserved putative Stat3 binding sites, miR-21 has been described 
as an oncogenic miRNA exhibiting antiapoptotic activity in various carcinomas.11-13 The putative 
regulatory region of the miR-21 gene is located within an intron of the overlapping 
transmembrane protein 49 (TMEM49) gene and contains two consensus Stat3 binding sites 
approximately 800 bp upstream of the transcription start site. It is evident from Fig. 1A that the 
Stat3 sites and the surrounding region, spanning 300 bp, are highly conserved in vertebrates at 
least since the common ancestor of tetrapods and actinopterygian fish, i.e. since the first 
evolutionary appearance of miR-21 and Stat3 in species for which genome-wide data are 
available. 
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Fig. 1. A highly conserved enhancer is responsible for the Stat3-mediated responsiveness of the miR-21 
promoter to IL-6. (A)  130-bp regions containing two predicted Stat3 binding sites upstream of the miR-21 genes of 
various vertebrate species are aligned. T, G, C, and A nucleotides are coloured green, orange, blue and red, 
respectively. Stat3 sites are highlighted by yellow boxes. Sequences from organisms where no genomic sequence 
was available were obtained from the Ensembl trace repository (as marked with a star, see supplemental Table S2). 
(B) XG-1 cells were deprived of IL-6 for 72 hours or restimulated for 30 min and subjected to a ChIP assay using 
anti-Stat3 or IgG isotype control. Co-immunoprecipitated DNA was amplified by PCR with primers specific for the 
miR-21 upstream enhancer. (C) Reporter gene assays were performed in HepG2 cells transfected either with a 
luciferase vector driven by the miR-21 promoter/enhancer alone (-) or in the presence of a vector encoding a small 
hairpin RNA silencing Stat3 expression (siStat3), or with a miR-21 promoter/enhancer construct containing point 
mutations in both Stat3 sites (∆Stat3). Values represent the mean luciferase activities ± standard deviation of 3 
independent experiments relative to samples from unmanipulated IL-6-treated cells.  
 
Genomic data suggest that miR-21 and its associated Stat3 binding sites are functionally 
independent of TMEM49 (supplemental Table S1). A stable distance between miR-21 and the 
Stat3 sites throughout all vertebrates strongly suggests their functional correlation (supplemental 
Fig. S1).  
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Chromatin immunoprecipitation revealed that Stat3 is indeed recruited to the miR-21 upstream 
region in XG-1 human myeloma cells in response to IL-6 (Fig. 1B). Furthermore, a genomic 
DNA fragment extending from -1120 to +25 bp relative to the miR-21 transcription start site14 
and containing the putative Stat3 enhancer region proved to be IL-6-responsive in a reporter 
assay (Fig. 1C). IL-6-induced miR-21 promoter activity was abolished when the Stat3 motifs 
were eliminated by site-directed mutagenesis. Likewise, knocking down Stat3 by RNA 
interference inhibited miR-21 promoter activity. The effects of Stat3 knockdown could be rescued 
by expression of an siRNA-resistant variant of Stat3 (supplemental Fig. S2). These data 
demonstrate the existence of a functional Stat3-regulated enhancer upstream of the miR-21 gene, 
as predicted by the bioinformatic analysis. 
To verify that IL-6 induces the transcription of the miR-21 gene, primary miR-21 transcripts (pri-
miR-21) and mature miR-21 were quantified by real-time PCR in XG-1 and INA-6 myeloma 
cells. IL-6 increased pri-miR-21 expression substantially in either cell line (Fig. 2A). Upon Stat3 
knock-down, comparable reductions of Stat3 mRNA and pri-miR-21 levels were observed (Fig. 
2B) proving that miR-21 induction by IL-6 is mediated by Stat3. Induction of miR-21 expression 
by IL-6 is not restricted to multiple myeloma as it is observed in other tumor cell lines as well 
(supplemental Fig. S3). Taken together, our data demonstrate that miR-21 gene transcription is 
controlled by IL-6 and requires Stat3. In contrast to the rapid induction of pri-miR-21, mature 
miR-21 levels raised slowly in XG-1 cells, eventually reaching a 4-fold increase (Fig. 2C). The 
same was observed in prostate carcinoma cells (supplemental Fig. S3) indicating a rather slow 
processing rate of pri-miR-21.  
Since miR-21 is involved in the control of tumor cell apoptosis11-13 we reasoned that it might 
contribute to the Stat3-dependent survival of myeloma cells. Due to relatively high basal miR-21 
expression levels, a miR-21 knock-down might cause effects that go beyond Stat3 regulation. 
Therefore, we chose to ectopically elevate miR-21 expression in the absence of IL-6 to levels 
comparable to those observed in response to Stat3 activation. Upon electroporation of INA-6 
cells with a miR-21 expression vector and sorting the transfected cells, we determined a 2.4-fold 
increase in mature miR-21 expression over endogenous levels by real-time PCR analysis (mean 
of three independent experiments). As reported earlier,5 IL-6 withdrawal rapidly induced 
apoptosis in INA-6 cells (Fig. 2D). Raising miR-21 expression, however, yielded significantly 
higher levels of non-apoptotic cells (Fig. 2E). This effect was most dramatic in the absence of 
IL-6, reducing the cytokine-dependency of the INA-6 cells.  
 




Fig. 2. miR-21 is induced by IL-6 via Stat3 activation and promotes survival of myeloma cells. (A) XG-1 and 
INA-6 cells were either restimulated with IL-6 for the times indicated after cytokine withdrawal for 72 and 12 h, 
respectively, or continuously cultured with IL-6 (perm.). Levels of pri-miR-21 were determined by real-time PCR. 
Values obtained for cells deprived of IL-6 were set to 1. (B) XG-1 and INA-6 cells cultured in the presence of IL-6 
were transiently transfected with an expression plasmid for a small hairpin RNA silencing Stat3 (grey boxes) or a 
scrambled sequence RNA (open boxes) together with a vector encoding enhanced green fluorescence protein. 
Successful downregulation of Stat3 protein levels under these conditions has been demonstrated by us previously.9 
After 48 h, green fluorescing cells were sorted, and Stat3 and pri-miR-21 transcript levels determined by real-time 
PCR. Values for the control samples were taken as reference. (C) In XG-1 cells treated as above, mature miR-21 was 
quantified by stem-loop reverse transcription followed by real-time PCR.10 (D,E) INA-6 cells were transiently 
transfected by electroporation with a control (D) or a miR-21 expression vector (E). An expression plasmid encoding 
enhanced green fluorescent protein was cotransfected. One day posttransfection, cell culture was continued either in 
the presence or absence of IL-6. After additional 24 or 48 h, apoptosis was studied by flow cytometric Annexin V 
assay, with the transfected cells gated on the basis of green fluorescence. In (D), the reduced levels of viable 
(Annexin V-negative) cells after cytokine withdrawal are represented relative to those observed in IL-6-treated cells. 
Graph E shows the relative percentage of viable cells with miR-21 expression vector relative to control vector 
transfection. Data represent mean values ± standard deviation from three independent experiments.  
 
 
Equivalent observations were made in XG-1 cells (data not shown). In summary, these data 
provide strong evidence that induction of miR-21 contributes to the antiapoptotic function of 
Stat3.  
Stat3 controls the expression of a number of antiapoptotic proteins on the transcriptional level, 
including survivin, Bcl-2, and Mcl-1,15-18 thereby providing an important fast-track survival 
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signal for myeloma and presumably other tumor cells. However, recent data suggest that this 
regulatory route does not sufficiently explain the full antiapoptotic potential of Stat3.5,19 As 
demonstrated here, miR-21 induction by Stat3 represents a rather slow-acting yet long-lasting 
survival stimulus, which appears as an ideal complementation of the immediate induction of 
antiapoptotic proteins. Overexpression of miR-21 has been reported for numerous cancers,11,20,21 
all of which contain constitutively activated Stat3 or even rely on Stat3 with respect to cell 
survival or growth.11,12,15,16,22 Taken together, our observations strongly suggest a pivotal 
relevance of miR-21 for the oncogenic potential of Stat3 and thereby for its involvement in the 
pathogenesis of multiple myeloma and other malignancies. 
Since miRNAs function as negative regulators of the stability and/or translation of specific target 
mRNAs, an important step to unravel the molecular mechanism of miR-21 action will be to 
identify its mRNA targets. Recently, miR-21 was reported to repress the expression of the tumor 
suppressor PTEN.12 Yet, we did not detect upregulation of PTEN expression or AKT 
phosphorylation in INA-6 and XG-1 cells in response to IL-6 (data not shown).  
Stat3 is regarded a promising target for tumor therapy.23-25 However, its involvement in the 
control of numerous cellular processes may cause adverse side effects of such treatments. The 
identification of miR-21 as a Stat3 target gene may provide an even more selective and promising 
target for future therapeutic strategies. 
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